Lars Z.
- Country
- Germany
- Department
- Gastroenterology
Research Overview
- Top‑down mirikizumab versus azathioprine standard of care in newly diagnosed moderate‑to‑severe Crohn’s disease: 52‑week randomised open‑label trial
- Evaluation of MORF-057 Efficacy and Safety in Adults with Moderately to Severely Active Crohn's Disease: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide in Mild to Moderately Active Ulcerative Colitis Patients
Data & Insights
Has run more than one trial at 33 of 153 partner sites.
Specializations
Ulcerative Colitis Therapeutics
Clinical research activity centers on ulcerative colitis, with attention to patients ranging from mildly to moderately active disease to newly diagnosed moderate-to-severe presentations. The work reflects a strong interest in improving control of intestinal inflammation and supporting durable remission in gastroenterology.
- Symptomatic remission
- Endoscopic response
- Histologic improvement
- Clinical remission
The therapeutic focus includes both induction and maintenance strategies aimed at comprehensive disease control in inflammatory bowel disease.
Crohn’s Disease and Inflammatory Bowel Disease
Research involvement also extends to Crohn’s disease, alongside broader inflammatory bowel disease care. This area supports clinical interest in chronic relapsing intestinal disorders that require long-term treatment planning and careful assessment of disease activity.
- Severely active disease
- Intestinal inflammation
- Disease control
The clinical landscape suggests engagement with therapies intended to reduce inflammatory burden and improve patient outcomes across complex bowel disease phenotypes.
Advanced Immunomodulatory Therapy
Another area of interest is the evaluation of targeted treatment approaches for ulcerative colitis, including mirikizumab and azathioprine with glucocorticoids. The research focus is aligned with comparative treatment strategies in patients needing escalation beyond conventional care.
- Biologic therapy
- Immunosuppressive treatment
- Standard of care
- Comprehensive disease control
This includes interest in therapies designed to improve inflammatory disease management through more precise immune modulation.
Maternal and Lactation Safety
Clinical research also covers mirikizumab exposure during breastfeeding, reflecting concern for treatment safety in lactating participants receiving therapy for an approved indication. This adds a reproductive and maternal-health dimension to the investigator’s therapeutic profile.
- Breast milk exposure
- Lactating participants
- Therapeutic safety
The area links gastroenterology with medication safety considerations in women requiring ongoing biologic treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.